Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.
about
Innate Immune Defenses in Human Tuberculosis: An Overview of the Interactions between Mycobacterium tuberculosis and Innate Immune CellsInnovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide AnalysesIncreased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis AntigenImmune responses to the enduring hypoxic response antigen Rv0188 are preferentially detected in Mycobacterium bovis infected cattle with low pathologyBacterial invasion of vascular cell types: vascular infectology and atherogenesis.Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosisWhole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analysesPotential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting.Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic areaImmunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosisRecombinant BCG as a vaccine vehicle to protect against tuberculosis.In vivo persistence and protective efficacy of the bacille Calmette Guerin vaccine overexpressing the HspX latency antigen.Evaluation of the humoral immune response and cross reactivity against Mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis.Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopesM.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model.Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals.ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.CD8+ regulatory T cells, and not CD4+ T cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cellsAdaptation to environmental stimuli within the host: two-component signal transduction systems of Mycobacterium tuberculosis.Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen.A Mycobacterium tuberculosis Dormancy Antigen Differentiates Latently Infected Bacillus Calmette-Guérin-vaccinated Individuals.MprA and DosR coregulate a Mycobacterium tuberculosis virulence operon encoding Rv1813c and Rv1812c.HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule.Tuberculosis subunit vaccines: from basic science to clinical testing.New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections.Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa.Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection.Molecular findings and approaches spotlighting Mycobacterium bovis persistence in cattle.Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria.Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K.Tuberculosis vaccines: present and future.DIVA reagents for bovine tuberculosis vaccines in cattle.An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time.Construction and immunogenicity of the DNA vaccine of Mycobacterium Tuberculosis dormancy antigen rv1733c.Improved Serodiagnostic Sensitivity of Strip Test for Latent Tuberculosis.Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.Mycobacterium tuberculosis Latent Antigen Rv2029c from the Multistage DNA Vaccine A39 Drives TH1 Responses via TLR-mediated Macrophage Activation.Cloning, optimization of induction conditions and purification of Mycobacterium tuberculosis Rv1733c protein expressed in Escherichia coli.Boosting with recombinant MVA expressing M. tuberculosis α-crystallin antigen augments the protection imparted by BCG against tuberculosis in guinea pigs.
P2860
Q26799901-64C35716-ECB3-42FC-9298-0966D2BFFE6FQ27027110-4FEA524A-6FB6-454A-86EB-A28D90BA0A32Q27302995-0F3E1964-A495-4C41-85D8-9B07F02FAB00Q27334541-3A5F1990-10C4-44D8-A353-794B563B82DAQ27692034-2F31FAB1-9ACB-4EDF-A266-936F1136BE00Q28077155-F6F10991-8633-4E76-B104-97D4AF73D2E4Q31156691-5BEB4A77-843A-426F-B533-B9B566A95C8BQ34133162-585DD6D4-9729-47E1-80C6-38BCFE1A9A6DQ34302593-F9949B5E-AB81-407D-A91B-89FA7355EE34Q34306108-F650955D-E298-4E67-8BC2-596BA03F6AD2Q34518560-ACCE34FA-CB05-4651-BFDC-822728FC510AQ34558242-5652DB22-E07E-4D8F-9BB4-C265B882363EQ34607513-E337777D-A547-49D8-8623-79A9AB149A19Q34985591-30716D79-0C82-4475-927E-CA7CA5AB070BQ35022769-234CFCB5-8936-4944-8C45-2D16528B9C75Q35066262-C8869A62-5186-4B51-B666-9D5A7A51CF74Q35069386-FCA1808B-E683-42DD-B949-456166F60F05Q35143070-AFAB6C5A-1A85-4D91-8DD4-BBE9BF1BD991Q35598334-A01710E9-FA98-4FBC-8286-489911595AE1Q35826596-60EA868B-02D1-4BCE-AE3E-B78D4FEC45FFQ36038593-F463E6B8-58A6-41C8-A205-D1F4259D247AQ36163086-816693D3-978C-46BE-83CC-C7008E0F421FQ36439241-5DC920DF-144D-4F24-ACA4-B24BADDA72BFQ36960497-B053B567-7EDB-41EC-AA8E-D9B99377DE67Q37150326-0F80DB9C-63B8-447B-B8FE-18B814475FDAQ37301865-32B805EE-2930-47B1-AD3D-A46981DB34F4Q37309256-D59CDAA8-1E2A-4808-A9CD-71FFAF2CC392Q37394401-B6634D01-FCF4-432F-99F5-10AEAD19115CQ37410301-F5EDEDD8-1B09-4E77-AC9C-351798733E7EQ37665484-08B769C2-B328-4C72-967A-0F01D93EA76DQ37685973-F98D4EE3-F332-4146-9C8A-493B2AB11B88Q37754908-B0EDF4BD-E499-4744-AFEC-9A2DD98865B6Q37909428-8A195284-2187-44CF-882D-B0D3254CA3C9Q38041566-3420F3D2-FA88-4869-B0AD-5B42E66F8CC7Q39026915-7DE0242B-C3D5-4458-BCC5-43650E94462EQ40111089-493A8B56-C9BF-4F9E-BD90-0927FADB00EBQ40706013-C6276ED1-5D0F-4820-84D8-D49AA4072A8BQ47102547-E0C6D3E6-7DDA-492D-ADCF-5CFAE90D398CQ47154222-623CBC89-7122-4A39-A63C-CE2DF7062F13Q47155139-9F5074E2-8F1C-4671-97E1-323DE6918547
P2860
Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lack of immune responses to My ...... cterium bovis BCG vaccination.
@ast
Lack of immune responses to My ...... cterium bovis BCG vaccination.
@en
type
label
Lack of immune responses to My ...... cterium bovis BCG vaccination.
@ast
Lack of immune responses to My ...... cterium bovis BCG vaccination.
@en
prefLabel
Lack of immune responses to My ...... cterium bovis BCG vaccination.
@ast
Lack of immune responses to My ...... cterium bovis BCG vaccination.
@en
P2093
P2860
P356
P1476
Lack of immune responses to My ...... cterium bovis BCG vaccination.
@en
P2093
Amanda L Stewart
Annemieke Geluk
Annemieke H Friggen
Kees L M C Franken
Krista E van Meijgaarden
Marleen J C Verduyn
Martin I Voskuil
May Young Lin
Michèl R Klein
Steven G Smith
P2860
P304
P356
10.1128/IAI.01999-06
P407
P577
2007-05-14T00:00:00Z